You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaNervous SystemProduct ClassPsychoanalepticsPharmacological SubgroupAnti-Dementia DrugsChemical SubgroupAnticholinesterasesCondition StudiedAlzheimer Disease
Sponsor Protocol NumberGAL-INT-1Enrollment653Data PartnerJohnson & Johnson% Female63.0%Mean/Median Age (Years)72.0% WhiteN/A
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0352 : ALL-EMBRACED: clinicAL triaLs web-sErvice to Modify eligiBility cRiteria and pre-screening viA artifiCial intElligence methoDs
- 2024-0840 : Gender differences in the efficacy of anti-dementia medication in Alzheimer’s disease: a systematic review
- 2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2021-4743 : Machine Learning Approaches to Predicting Treatment Outcomes in Alzheimer's Disease
- 2020-4448 : Reanalysis of Alzheimer's Disease Clinical Trials Using Longitudinal Latent Trait Models
- 2016-0765 : Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The 'Optimising the Analysis of Cognition' Collaboration